Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company dedicated to developing vaccines to prevent infectious diseases. Based in Gaithersburg, Maryland, with facilities in Rockville, Maryland, and Uppsala, Sweden, Novavax employs over 300 professionals focused on innovation in vaccine development.
Novavax leverages its proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant to create vaccines that stimulate strong immune responses. The company's product pipeline includes vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus. Additionally, their pipeline includes preclinical programs targeting various infectious diseases.
Recently, Novavax has made significant strides in COVID-19 vaccine development. The company announced that its Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) received Emergency Use Listing (EUL) from the World Health Organization (WHO). This listing expedites the regulatory approval process, enabling broader global distribution. The vaccine is also authorized in the U.S. and the European Union and is under review in other markets.
Novavax's updated COVID-19 vaccine can be stored at temperatures between 2 to 8 degrees Celsius and has a 12-month shelf life, simplifying logistics and reducing waste. This vaccine has shown efficacy against multiple variants, including BA.2.86, EG.5.1, and XBB.1.16.6.
In addition to their COVID-19 efforts, Novavax has entered a co-exclusive licensing agreement with Sanofi to enhance the distribution of their standalone adjuvanted COVID-19 vaccine and develop combination vaccines. This partnership highlights the company's commitment to leveraging its technology to address global health challenges.
Financially, Novavax has shown a strong performance with updated financial guidance for 2024. With over $1 billion in potential contract value for advance purchase agreements, Novavax is well-positioned to deliver on its commitments while focusing on expanding its product portfolio.
Overall, Novavax Inc. represents a significant player in the biotechnology sector, continuously pushing the boundaries of vaccine development to address pressing global health issues.
Novavax initiated PREVENT-19, a pivotal Phase 3 trial in the U.S. and Mexico to assess the efficacy and safety of NVX-CoV2373, its COVID-19 vaccine candidate. The study aims to enroll up to 30,000 participants, with two-thirds receiving the vaccine and one-third a placebo. Previous Phase 1/2 trials demonstrated a robust immune response. Supported by Operation Warp Speed, this trial is critical for developing vaccines to combat the pandemic. Results from this and other ongoing studies are expected soon, potentially influencing vaccine availability.
Novavax (Nasdaq: NVAX) announced the appointment of Rick Crowley as Executive Vice President, Chief Operations Officer. Crowley will oversee all operations, including Quality, Manufacturing, Supply Chain, and Regulatory Affairs, taking over from Ben Machielse, who will remain as an executive advisor. Crowley brings extensive experience in biopharmaceuticals, having previously held senior roles at TerSera and Crealta. Novavax aims to leverage Crowley's expertise to enhance its manufacturing capabilities and advance its COVID-19 and influenza vaccine candidates.
Novavax, Inc. (Nasdaq: NVAX) has entered into an Advance Purchase Agreement with the New Zealand government for 10.7 million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The vaccine, currently in Phase 3 clinical trials in the UK, utilizes Novavax's proprietary Matrix-M™ adjuvant to boost immune response. Initial deliveries are targeted for mid-2021, pending regulatory approvals. Novavax aims to ensure vaccine accessibility for New Zealanders, reflecting confidence in its candidate amid the ongoing pandemic.
Novavax, Inc. (Nasdaq: NVAX) has appointed Margaret G. McGlynn, R. Ph., as an independent director on its board. McGlynn brings significant experience in vaccine commercialization and public health, which will be crucial as Novavax approaches the Phase 3 data collection for its COVID-19 vaccine candidate, NVX-CoV2373. With a strong background from the International AIDS Vaccine Initiative and Merck, she aims to bolster Novavax's mission to distribute the vaccine globally. Currently, Novavax is also advancing its quadrivalent influenza nanoparticle vaccine.
Novavax, Inc. (Nasdaq: NVAX) has announced significant progress in its COVID-19 vaccine program, NVX-CoV2373. The pivotal Phase 3 trial in the U.K. is fully enrolled with 15,000 participants, while the Phase 2b trial in South Africa has also completed enrollment with 4,422 participants. A Phase 3 trial in the U.S. and Mexico is set to commence soon. The company has garnered $1.6 billion in funding from the U.S. government and anticipates interim data from these trials in early 2021, potentially supporting global regulatory applications.
Novavax (Nasdaq: NVAX) announced participation in two investor conferences to discuss its COVID-19 vaccine candidate, NVX-CoV2373. The first is the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, featuring a panel discussion moderated by Edward A. Tenthoff and Yasmeen Rahimi, with Dr. Gregory M. Glenn as a panelist. The second event is the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, which includes a fireside chat and investor meetings. NVX-CoV2373 is currently in various stages of clinical trials and has secured $2 billion in funding for its vaccine program.
Novavax is set to host a live Q&A conference call on November 10, 2020, due to technical difficulties during its quarterly earnings call on November 9. The session invites the investment community to discuss the Company's third-quarter financial and operational results. The call will commence at 4:30 p.m. ET, following the close of U.S. financial markets, with details available on Novavax's website. A replay will be accessible until November 17, 2020.
Novavax (NVAX) reported a net loss of $197.3 million for Q3 2020, significantly higher than the $18 million loss in Q3 2019. Revenue reached $157 million, boosted by funding for NVX-CoV2373, its COVID-19 vaccine candidate, which has entered a Phase 3 trial in the U.K. with 15,000 participants. The company secured over $2 billion in funding from various sources for clinical development. Manufacturing capacity for NVX-CoV2373 is set to exceed two billion doses by mid-2021. Novavax is also advancing its NanoFlu program with a new leadership team.
Novavax, a late-stage biotechnology firm, has announced leadership changes aimed at enhancing its commercialization strategy. Gregory F. Covino joins as CFO, bringing extensive global financial expertise. John Trizzino shifts from CFO to Chief Commercial Officer to focus on advancing the COVID-19 vaccine candidate NVX-CoV2373 and NanoFlu. Filip Dubovsky is promoted to Executive Vice President and Chief Medical Officer, while Biegie Lee becomes Senior Vice President and Chief Information Officer.
These changes are crucial as Novavax prepares to enter global markets with its promising vaccine candidates.
Novavax (Nasdaq: NVAX) has received Fast Track Designation from the FDA for its COVID-19 vaccine candidate, NVX-CoV2373. This designation aims to expedite the development and regulatory review process, highlighting the urgent need for an effective vaccine. The Phase 3 clinical trial in the U.S. and Mexico is expected to begin by the end of November 2020, with interim data anticipated from the UK trial in early 2021. Novavax has secured $2 billion in funding for its global vaccine program.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
What is Novavax Inc. known for?
Where is Novavax Inc. headquartered?
What recent achievements has Novavax made?
What is the storage requirement for Novavax's COVID-19 vaccine?
Who are Novavax’s main partners?
What are the key products in Novavax's pipeline?
How does Novavax’s Matrix-M™ adjuvant work?
What financial performance is expected from Novavax in 2024?
Is Novavax's COVID-19 vaccine effective against variants?
What is the significance of Novavax's partnership with Sanofi?
